Latest Breaking News On - Giles platford - Page 1 : comparemela.com

A Decade Of Innovation: How This CEO Transformed A Global Pharma Giant

In a decade, Christophe Weber remade Takeda into a global pharma leader, shifting from a fragmented structure to a unified innovator.

United statesUnited kingdomChristophe weberGiles platfordJulie kimPallavi gargTakeda qdengaTakeda pharmaceuticalPlasma derived therapiesEmerging marketsGlobal oncology productsNarcolepsy typePlaque psoriasisHealth careLife sciencesRare disease

Takeda s HyQvia receives EC approval for rare neuromuscular disorder CIDP

Takeda s HyQvia receives EC approval for rare neuromuscular disorder CIDP
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Kristina allikmetsGiles platfordTakeda hyqviaEuropean commissionDrug administrationPlasma derived therapies business unit

FDA approves Hyqvia for chronic inflammatory demyelinating polyneuropathy

FDA approves Hyqvia for chronic inflammatory demyelinating polyneuropathy
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Halozyme enhanzeGiles platfordCaroll diberardinoTakeda pharmaceutical

Takeda s HyQvia granted FDA approval to treat rare neuromuscular disorder CIDP

Takeda s HyQvia granted FDA approval to treat rare neuromuscular disorder CIDP
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Elisa butlerTakeda hyqviaGiles platfordFoundation internationalDrug administrationPlasma derived therapies business unit

FDA Approves IgG-Hyaluronidase Recombinant for the Treatment of Adult Patients With CIDP

Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.

Elisa butlerGiles platfordFoundation internationalPlasma derived therapies business unit